The development of novel small molecule therapeutics has long been constrained by fundamental limitations in molecular exploration. Traditional approaches screen thousands of compounds to identify a single viable candidate and often fail to account for the intricacies of drug-target interactions, leading to high attrition rates in clinical trials.
READ MOREWhat if you could predict the next breakthrough molecule before your competitors even begin screening?
READ MORETo help our clients make informed decisions about new technologies, we have opened up our research & development facilities and actively encourage customers to try the latest platforms using their own tools and if necessary together with their existing hardware. Remote access is also available
Boston's annual Technology Innovation Day is back for 2025 and this year we're at The Grove!